000 03015nam  2200361za 4500
0019.852907
003CaOODSP
00520210625034144
007cr |||||||||||
008180305s2018    onc     ob   f000 0 eng d
020 |a9780660255545
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-210/2018E-PDF
24500|aLiterature review update on the efficacy and effectiveness of high-dose (Fluzone® High-Dose) and MF59-adjuvanted (Fluad®) trivalent inactivated influenza vaccines in adults 65 years of age and older |h[electronic resource].
24617|aEfficacy and effectiveness of high-dose and MF59-adjuvanted trivalent inactivated influenza vaccines in adults 65 years of age and older
2461 |iAt head of title: |aAdvisory committee review, National Advisory Committee on Immunization (NACI)
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2018.
300 |a39 p.
500 |aIssued also in French under title: Mise à jour sur la revue de la littérature portant sur l’efficacité potentielle et réelle des vaccins antigrippaux trivalents inactivés à forte dose (FluzoneMD Haute dose) et contenant l’adjuvant MF59 (FluadMD) chez les adultes âgés de 65 ans et plus.
500 |aCover title.
500 |a"Publication date: May 2018."
500 |aPrepared by: L. Zhao ... [et al.]. Cf. Acknowledgements.
504 |aIncludes bibliographical references (p. 17-19).
516 |aElectronic monograph in PDF format.
520 |a“Two trivalent inactivated influenza vaccines (TIVs) designed specifically for adults 65 years of age and older are currently authorized for use in Canada: a high-dose vaccine (Fluzone® High-Dose, Sanofi Pasteur) and an MF59-adjuvanted vaccine (Fluad®, Seqirus). Previous literature reviews on the efficacy and effectiveness, immunogenicity and safety of Fluzone® High-Dose and Fluad® have been conducted to inform NACI’s recommendations on the use of these vaccines in the annual NACI Advisory Committee Statement: Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine. To ensure that these recommendations continue to be informed with the most current literature, the present literature review was conducted to identify additional efficacy and effectiveness evidence published since the original literature reviews”--Executive summary, p. 4.
69207|2gccst|aSeniors
69207|2gccst|aImmunization
69207|2gccst|aInfluenza
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tMise à jour sur la revue de la littérature portant sur l’efficacité potentielle et réelle des vaccins antigrippaux trivalents inactivés à forte dose (FluzoneMD Haute dose) et contenant l’adjuvant MF59 (FluadMD) chez les adultes âgés de 65 ans et plus |w(CaOODSP)9.852908
85640|qPDF|s449 KB|uhttps://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-210-2018-eng.pdf